Alterity Therapeutics Issues Notification Regarding Unquoted Securities

Alterity Therapeutics Limited filed a Form 6-K on April 20, 2026, to provide a notification regarding unquoted securities. The filing serves as a formal report to the SEC for the month of April 2026 and incorporates the information by reference into several of the company's existing Registration Statements on Form S-8 and Form F-3. Specifically, the document includes Exhibit 99.1, which is a notification regarding unquoted securities (ATH). The filing was signed by Julian Babarczy, the Chairman of the company. No specific details regarding the volume, pricing, or terms of the unquoted securities were provided in the summary text of the 6-K itself, and no clinical trial updates or regulatory milestones were mentioned in this specific document. Alterity Therapeutics remains a development-stage enterprise focused on biotechnological advancements.